Conference Coverage

An enlightened approach to weight loss using liraglutide


 

AT OBESITY WEEK 2016

This analysis and the clinical trials on which it was based were sponsored by Novo Nordisk, which markets liraglutide under the brand names Saxenda and Voctoza. The presenter reported receiving research grants from and serving as a consultant to Novo Nordisk and other pharmaceutical companies.

Pages

Recommended Reading

Gas-filled gastric balloons achieve weight loss
MDedge Cardiology
Obesity paradox extends to TAVR but not SAVR
MDedge Cardiology
Obesity continues to trend up among women over the past decade
MDedge Cardiology
Adolescent obesity rose slightly, again
MDedge Cardiology
Phentermine-topiramate shows best chance of weight loss at 1 year
MDedge Cardiology
Pioglitazone safe and effective for steatohepatitis in T2DM
MDedge Cardiology
Metabolic health declining among the obese, despite improvements in BP and lipids
MDedge Cardiology
Overweight, obesity increase risk of cardiotoxicity from anthracyclines
MDedge Cardiology
Study shows faster increase in obesity prevalence among cancer survivors
MDedge Cardiology
AHA: Limit children’s added sugar intake to 25 g/day
MDedge Cardiology